Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;13(2):1014-1018.
doi: 10.3892/ol.2016.5483. Epub 2016 Dec 12.

Primary breast lymphoma: A single center study

Na Zhang  1 , Caineng Cao  1 , Yuan Zhu  1 , Peng Liu  1 , Luying Liu  1 , Ke Lu  1 , Jialin Luo  1 , Ning Zhou  1
Affiliations

Primary breast lymphoma: A single center study

Na Zhang et al. Oncol Lett. 2017 Feb.

Abstract

The aim of the present study was to summarize the clinical characteristics of primary breast lymphoma (PBL) and evaluate its management approaches. A total of 29 patients newly diagnosed with PBL, and treated between April 2006 and May 2013, were analyzed retrospectively. The median survival follow-up time for all patients was 66.8 (range, 25.4-110.0) months. The results of the follow-up revealed 22 living lymphoma-free patients and 7 patients who had succumbed to PBL. Of the 7 deceased patients, 6 had succumbed to lymphoma and 1 to chemotherapy-associated hepatic failure. In total, 1 patient who presented with bilateral breast lymphoma developed left breast relapse following lumpectomy and chemotherapy, 2 patients developed a bone marrow relapse, 1 patient developed lung and mediastinal lymph node relapses, and 1 patient developed a skin relapse. The Kaplan-Meier estimator predicted 5-year overall survival and progression-free survival rates for all patients of 74.4 and 74.6%, respectively. PBL appears to be a rare disease with a good overall prognosis and low incidence of local relapse, following chemotherapy alone or in combination with other treatments. Further studies investigating the development of effective agents for use in treatment-resistant patients are required.

Keywords: diffuse large B cell lymphoma; primary breast lymphoma; prognosis; treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier curve showing the OS and PFS rates of patients with primary breast lymphoma in the present study. OS, overall survival; PFS, progression-free survival.
See this image and copyright information in PMC

References

    1. Dobrotina AF, Zlotnikova ZB. Generalized sarcomatosis (lymphosarcomatosis) in pregnancy with unusual bilateral involvement of the breasts. Vopr Onkol. 1959;5:613–616. (In Russian) - PubMed
    1. Aviv A, Tadmor T, Polliack A. Primary diffuse large B-cell lymphoma of the breast: Looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol. 2013;24:2236–2244. doi: 10.1093/annonc/mdt192. - DOI - PubMed
    1. Caon J, Wai ES, Hart J, Alexander C, Truong PT, Sehn LH, Connors JM. Treatment and outcomes of primary breast lymphoma. Clin Breast Cancer. 2012;12:412–419. doi: 10.1016/j.clbc.2012.07.006. - DOI - PubMed
    1. Jeanneret-Sozzi W, Taghian A, Epelbaum R, Poortmans P, Zwahlen D, Amsler B, Villette S, Belkacémi Y, Nguyen T, Scalliet P, et al. Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study. BMC Cancer. 2008;8:86. doi: 10.1186/1471-2407-8-86. - DOI - PMC - PubMed
    1. Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, Roos D, Lennard A, Devizzi L, Crabb S, et al. Primary diffuse large B-cell lymphoma of the breast: Prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2008;19:233–241. doi: 10.1093/annonc/mdm471. - DOI - PubMed